

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1 - 30 (cancelled)

1               31 (currently amended): A method for treating an ophthalmic disorder in a  
2 mammal, said method comprising administering to the eye of said mammal a lipid formulation,  
3 said lipid formulation comprising:

4               a lipid phase, said lipid phase comprising a phospholipid neutral lipid and a  
5 modifying agent, wherein said modifying agent is a member selected from the group consisting  
6 of cationic lipids and mucoadhesive compounds;

7               an aqueous phase; and

8               a therapeutic agent, wherein said therapeutic agent in said lipid formulation is  
9 useful for treating said ophthalmic disorder;

10               wherein said lipid formulation comprises about 0.001 to about 10.000 wt % of  
11 said lipid phase and about 90.000 wt % to about 99.999 wt % of said aqueous phase, and wherein  
12 said lipid phase comprises 0.01 to 10 wt% phospholipid, 0.1 to 10 wt % modifying agent and 0.1  
13 to 10 wt% antioxidant.

1               32 (original): The method in accordance with claim 31, wherein said ophthalmic  
2 disorder is post-operative pain.

1               33 (original): The method in accordance with claim 31, wherein said ophthalmic  
2 disorder is ocular inflammation.

1               34 (currently amended): The method in accordance with claim 33, wherein said  
2 ocular inflammation results from a member selected from the group consisting of iritis,

3 conjunctivitis, seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior  
4 uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars  
5 planitis, ~~masquerade syndromes including~~ ocular lymphoma, pemphigoid, scleritis, keratitis,  
6 severe ocular allergy, corneal abrasion and blood-aqueous barrier disruption.

1               35 (original): The method in accordance with claim 31, wherein said ophthalmic  
2 disorder is post-operative ocular inflammation.

1               36 (original): The method in accordance with claim 35, wherein said post-  
2 operative ocular inflammation results from a member selected from the group consisting of  
3 photorefractive keratectomy, cataract removal surgery, intraocular lens implantation and radial  
4 keratotomy.

1               37 (original): The method in accordance with claim 31, wherein said ophthalmic  
2 disorder is a fungal or bacterial infection.

1               38 (original): The method in accordance with claim 31, wherein said ophthalmic  
2 disorder is herpes ophthalmicus.

1               39 (original): The method in accordance with claim 31, wherein said ophthalmic  
2 disorder is endophthalmitis.

1               40 (original): The method in accordance with claim 31, wherein said ophthalmic  
2 disorder is intraocular pressure.

1               41 (original): The method in accordance with claim 31, wherein said therapeutic  
2 agent is diclofenac.

1               42 (original): The method in accordance with claim 41, wherein said diclofenac  
2 is diclofenac sodium.

1               43 (currently amended): A method for treating or preventing ocular  
2 inflammation, paracentesis-induced miosis, cystoid macular edema and mydriasis, said method

3 comprising administering a therapeutically effective amount of one or more non-steroidal anti-  
4 inflammatory drugs encapsulated or contained within a liposome formulation, said liposome  
5 formulation comprising 0.001 to 10.000 wt% lipid phase, and 90.000 to 99.999 wt% aqueous  
6 phase, wherein said lipid phase comprises 0.01 to 10 wt% phospholipid, 0.1 to 10% modifying  
7 agents and 0.1 to 10 wt% antioxidant.

1                  44 (original): The method in accordance with claim 43, wherein said liposome  
2 formulation is applied topically, resulting in the transcorneal or transscleral passage or  
3 introduction of one or more non-steroidal anti-inflammatory drugs into the eye.

1                  45 (currently amended): The method in accordance with claim 43, wherein said  
2 lipid phase further comprises 0.0 to 90.0 wt% of one or more active agents, ~~10.0 to 100.0 wt%~~  
3 ~~phospholipid, 0.0 to 20.0 wt% antioxidant, and 0.0 to 20% modifying agents;~~ and said aqueous  
4 phase comprises 0.0 to 10.0 wt% one or more active agents, 0.0 to 5.0 wt% anti-microbial  
5 preservative, and 90.0 to 100.0 wt% aqueous solution.

1                  46 (original): The method in accordance with claim 45, wherein said active  
2 agent(s) are non-steroidal anti-inflammatory drugs.

1                  47 (original): The method in accordance with claim 46, wherein said non-  
2 steroidal anti-inflammatory drugs are selected from the group consisting of ketoprofen,  
3 flurbiprofen, ibuprofen, diclofenac, ketorolac, nepafenac, amfenac and suprofen.

1                  48 (original): The method in accordance with claim 47, wherein said non-steroidal  
2 anti-inflammatory drug is diclofenac.

1                  49 (currently amended): The method in accordance with claim 43, wherein said  
2 ocular inflammation is a symptom of iritis, conjunctivitis, seasonal allergic conjunctivitis, post-  
3 operative inflammation, acute and chronic endophthalmitis, anterior uveitis, uveitis associated  
4 with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, ~~masquerade~~

5    ~~syndromes including~~ ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy,  
6    corneal abrasion, blood-aqueous barrier disruption or ocular trauma.

1                50 (original): The method in accordance with claim 49, wherein said post-  
2    operative inflammation is caused by photorefractive keratectomy, cataract removal surgery,  
3    intraocular lens implantation or radial keratotomy.

51 - 52 (cancelled)